Coherus Oncology (CHRS) Financials

Coherus Oncology (NASDAQ: CHRS) showed a much stronger liquidity position in Q1 2026, but the company remains under pressure from persistent operating losses and a highly leveraged balance sheet. The latest quarter was dominated by cash raised from financing and investment activity rather than from core operations, while revenue remained modest relative to expenses.

What stands out most from the latest quarter:

• Cash and equivalents rose to $115.2 million at March 31, 2026, up from $103.4 million at the end of Q3 2025 and down sharply from the spike seen in mid-2025, but still a meaningful cash cushion.
• Including short-term investments of $51.8 million, CHRS ended Q1 2026 with about $167.0 million in liquid resources.
• Revenue in Q1 2026 was $12.3 million, slightly above Q4 2025 and Q3 2025, indicating some stabilization in the top line.
• Gross profit was $8.5 million, producing a gross margin of roughly 69%, which suggests the company’s products can still generate healthy product-level margins.
• The company raised $53.7 million from common equity issuance in Q1 2026, helping support liquidity.
• Net cash from investing activities was +$30.7 million, aided by $38.1 million of investment maturities/sales.

• Q1 2026 operating expenses remained elevated, with SG&A of $23.1 million and R&D of $21.5 million.
• The company still carries $37.1 million of long-term debt, though that is far below its equity base before the latest losses.
• A large portion of the balance sheet is made up of intangible and acquisition-related assets, including $45.6 million of goodwill.
• Shares outstanding remain high, and the company has relied on equity issuance to fund operations, which can weigh on per-share value.

• CHRS posted a net loss of $38.3 million in Q1 2026, or $0.28 per share, showing the business is still far from profitability.
• Operating loss was $36.2 million, because total operating expenses of $44.6 million were far above gross profit.
• Operating cash flow was deeply negative at -$57.9 million, meaning the core business consumed significant cash in the quarter.
• Total current liabilities of $132.3 million still exceed current assets excluding inventory and other less-liquid items, so short-term financial flexibility remains a concern.
• Retained earnings were -$1.42 billion, highlighting the scale of accumulated losses over time.
• Looking at the broader trend, revenue has fallen sharply from $54.1 million in Q4 2024 and $91.5 million in Q4 2023, showing that the business has not regained its former sales base.
• The company has relied on financing, asset sales, and other non-operating sources to support cash flow, rather than generating cash from operations.

Trend summary: Over the last four years of available quarterly data, CHRS has moved from periods of much higher revenue to a smaller, less consistent revenue base. That decline has not been matched by a proportional reduction in operating expenses, so losses have continued. The balance sheet has also become more volatile, with major swings in liabilities, equity, and cash tied to financing actions and asset transactions.

Bottom line: The Q1 2026 results show that CHRS still has liquidity and can access capital, but the core business remains unprofitable and cash-consuming. For retail investors, the key question is whether management can rebuild revenue while reducing operating burn before the company needs additional financing.